Related Experiment Video
Updated: May 21, 2026
06:49
The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy (rNAION)
Published on: November 20, 2016
Anterior ischemic optic neuropathy associated with udenafil
1Department of Ophthalmology, Maryknoll Hospital, Busan, Korea.
Korean Journal of Ophthalmology : KJO
|June 7, 2012
Summary
A case study links udenafil use to anterior ischemic optic neuropathy (AION), a serious eye condition. Discontinuation of udenafil led to the resolution of optic disc swelling.
Area of Science:
- Ophthalmology
- Neuro-ophthalmology
- Pharmacology
Background:
- Udenafil is a phosphodiesterase type 5 inhibitor used for erectile dysfunction.
- Anterior ischemic optic neuropathy (AION) is a common cause of sudden vision loss in older adults.
Observation:
- A 54-year-old male experienced acute visual field defects in his right eye after using udenafil.
- Clinical examination revealed a relative afferent pupillary defect and optic disc swelling.
- Ophthalmic imaging, including fluorescein angiography and optical coherence tomography, showed characteristic signs of AION.
Findings:
- Automated visual fields demonstrated an enlarged blind spot and visual field constriction.
- Fluorescein angiography indicated delayed choroidal and optic disc filling, along with late-phase leakage.
- Optical coherence tomography revealed increased retinal nerve fiber layer thickness.
Implications:
- This case highlights a potential association between udenafil and AION.
- Patients using udenafil should be monitored for visual disturbances.
- Prompt discontinuation of the medication may be crucial for managing AION.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...